AbbVie Wins Analyst Confidence With Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
AbbVie Wins Analyst Confidence With Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
艾伯维公司（NYSE:ABBV）周四发布了第二季度每股收益2.65美元，同比下降8.9％，超过2.57美元的共识。
Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.
净收入达到144.6亿美元，上涨了4.3％，超过了140.3亿美元的共识。销售收入在运营基础上上涨了5.6％。
Cantor Fitzgerald writes that quality 2Q24 earnings results support a positive investment thesis and increase confidence that growth will accelerate in 2025+. This high single-digit, above-market growth in 2025+ is not fully reflected in the stock's valuation yet.
康达菲茨杰写道，优质的2Q24盈利结果支持积极的投资论点，并增加了2025年及以后增长将加速的信心。尽管2025年及以后的高个位数市场增长尚未完全反映在股票估值中，但这一点得到了支持。
The analyst reiterates the Overweight rating, with a price target of $200.
分析师重申超配（Overweight）评级并给出200美元的价格目标。
Truist Securities maintains the Buy rating and increases the price target from 195 to $210. The analyst sees strong performance across AbbVie's diversified portfolio and potential for ongoing growth into the end of the decade.
Truist Securities维持买入评级并将价格目标从195美元提高到210美元。分析师看到了艾伯维公司多元化组合的强劲表现和持续增长的潜力。
Despite IRA's impact on Humira and Imbruvica, AbbVie continues to be set up for long-term growth led by key growth drivers Skyrizi and Rinvoq and ongoing momentum for the current portfolio of products and pipeline.
尽管IRA对Humira和Imbruvica产生了影响，但由关键业务的增长驱动，艾伯维公司仍然有着长期增长的潜力。其中包括Skyrizi和Rinvoq具有持续动力及现有产品和管线的势头。
Despite expectations for continued strong performance in Immunology, Goldman Sachs notes that Skyrizi and Rinvoq will maintain their growth momentum, driven by new-to-brand prescription (NBRx) trends indicating the potential for increased market share in inflammatory bowel disease (IBD) and the significant role of mechanism-of-action switching, particularly among CVS/biosimilar patients.
尽管预计免疫学领域的表现将继续强劲，但高盛指出Skyrizi和Rinvoq将保持其增长势头，这将受到新的独立处方（NBRx）趋势的推动，表明在炎症性肠病（IBD）市场份额有可能增加，机制作用切换则在CVS /仿制药患者中发挥着重要作用。由于这种治疗途径对艾伯维公司具有优势，目前的预测并未完全反映这一点。
This treatment pathway, which is advantageous for AbbVie, is not fully reflected in current forecasts.
这种治疗途径对艾伯维公司非常有利，但目前的预测并未完全反映这一点。
AbbVie's long-term growth outlook remains strong. Despite challenges in the aesthetics sector, management has assured that the Cerevel acquisition will close soon, possibly next week.
艾伯维公司的长期增长前景仍然强劲。尽管在美容业务方面存在一些挑战，但管理层已经确保了Cerevel的收购，可能会在下周关闭。
This development addresses a significant uncertainty and positions the company for several potential high-impact data catalysts in the second half of 2024 and into 2025.
这一进展解决了一个重大不确定因素，并为公司在2024年下半年和2025年产生了几个潜在的高影响数据触发器，为未来奠定了基础。
Goldman Sachs increases the price target from $190 to $200, reiterating the Buy rating.
高盛将评级从买入提高到增持，并将价格目标从190美元提高到200美元。
Needham writes that AbbVie reported a strong bounceback in the aesthetics business during the second quarter but reported some unexpected softness in the U.S. market.
Needham写道，艾伯维公司在第二季度的美容业务出现强劲反弹，但在美国市场报告了一些意外的疲软。
AbbVie reported lower-than-expected procedure growth and made some slight downward adjustments to their aesthetics guidance due to slower-than-expected near-term growth.
艾伯维公司报告称，由于近期增长速度未达预期，手术增长低于预期，因此对其美容业务的指导做出了轻微下调。
Price Action: ABBV stock is up 2.08% at $185.96 at last check Friday.
股票ABBV在上周五收盘时上涨2.08％至185.96美元。
Photo via Shutterstock
图片来自shutterstock。
- AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case.
- 艾伯维公司就长期的AndroGel案件向最高法院寻求律师-客户特权。